CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(03): 279-281
DOI: 10.1055/s-0041-1732823
Drug Review

Larotrectinib: A Novel Tumor-Agnostic Neurotrophic Tropomyosin Receptor Kinase (NTRK) Inhibitor in Advanced Solid Tumors

Manikandan Dhanushkodi
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
Jyoti Bajpai
2   Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Institutsangaben


Larotrectinib and entrectinib are highly selective, potent tropomyosin receptor kinase fusion inhibitors. It is U.S. Food and Drug Administration approved for the treatment of adult and pediatric advanced solid tumors with neurotrophic tropomyosin receptor kinase fusion genes who are refractory to standard systemic therapy. The response rate was ~80% and was rapid and durable. The median progression-free survival was 28 months. The side effects include anemia, weight gain, hepatotoxicity, and neuropsychiatric manifestations. Phase 3, randomized controlled trials are warranted to assess survival benefit.


Artikel online veröffentlicht:
18. August 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India